AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 28244559 — intervention group
Group type: COMPARATOR
Intervention: LOW-resistance (1x80-100 repetitions at 20%1RM)
Number of subjects: 47
Study 28244559 — intervention group
Group type: COMPARATOR
Intervention: Mixed-low LOW+ resistance
Number of subjects: 47
Study 26664396 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin (20 mg/day) plus Risperidone (6 mg/day)
Number of subjects: 40
Study 26664396 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus Risperidone (6 mg/day)
Number of subjects: 40
Study 23144046 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin-glucose infusion during the first 48 hours of hospitalization for AMI
Number of subjects: 578
Study 21755218 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational video for promoting attachment
Number of subjects: 24
Study 21755218 — intervention group
Group type: COMPARATOR
Intervention: Control group (no educational video)
Number of subjects: 24
Study 19663190 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined basic treatment with methotrexate (7.5 mg/week) and plaquenil (0.2 mg/day)
Number of subjects: 142
Study 19663190 — intervention group
Group type: COMPARATOR
Intervention: Methotrexate monotherapy
Number of subjects: 142
Study 16675725 — intervention group
Group type: EXPERIMENTAL
Intervention: Clopidogrel
Number of subjects: 103
Study 16675725 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 103
Study 15239097 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine 10 mg
Number of subjects: 32
Study 15239097 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine 50 mg
Number of subjects: 32
Study 15239097 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine 100 mg
Number of subjects: 32
Study 15239097 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine 200 mg
Number of subjects: 32
Study 15239097 — intervention group
Group type: EXPERIMENTAL
Intervention: Clevudine (all doses)
Number of subjects: 32
Study 11535908 — intervention group
Group type: EXPERIMENTAL
Intervention: Abdominal ultrasound during initial ED resuscitation
Number of subjects: 208
Study 11535908 — intervention group
Group type: COMPARATOR
Intervention: No ultrasound (control)
Number of subjects: 208
Study 9205761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg
Number of subjects: 30
Study 9205761 — intervention group
Group type: EXPERIMENTAL
Intervention: Cimetidine 800 mg
Number of subjects: 30
Study 9205761 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 30
Study 9205761 — intervention group
Group type: EXPERIMENTAL
Intervention: Ebrotidine 800 mg and Cimetidine 800 mg
Number of subjects: 30
Study 1770193 — intervention group
Group type: EXPERIMENTAL
Intervention: Total enteral nutrition (TEN) via needle catheter jejunostomy (NCJ) within 12 hours post-laparotomy.
Number of subjects: 63
Study 1770193 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN) after postoperative day 5.
Number of subjects: 63
Study 1770193 — intervention group
Group type: EXPERIMENTAL
Intervention: Total enteral nutrition (TEN) via NCJ during the same postoperative period.
Number of subjects: 63
Study 1770193 — intervention group
Group type: COMPARATOR
Intervention: Total parenteral nutrition (TPN).
Number of subjects: 63
Study 1770193 — intervention group
Group type: EXPERIMENTAL
Intervention: Total enteral nutrition (TEN).
Number of subjects: 63
Study 7066138 — intervention group
Group type: EXPERIMENTAL
Intervention: Extradural pethidine 25 mg with adrenaline 25 micrograms
Number of subjects: 20
Study 7066138 — intervention group
Group type: COMPARATOR
Intervention: Extradural pethidine 25 mg without adrenaline
Number of subjects: 20
Study 30462220 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower-dose edoxaban
Number of subjects: 1145
Study 30462220 — intervention group
Group type: EXPERIMENTAL
Intervention: Warfarin
Number of subjects: 1145
Study 30462220 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher-dose edoxaban
Number of subjects: 1145
Study 30462220 — intervention group
Group type: EXPERIMENTAL
Intervention: Study drug interrupted ≤3 days
Number of subjects: 1145
Study 30462220 — intervention group
Group type: EXPERIMENTAL
Intervention: Study drug interrupted >3 days
Number of subjects: 1145
Study 29051133 — intervention group
Group type: EXPERIMENTAL
Intervention: Web- and app-based health promotion tool (SoSu-life)
Number of subjects: 355
Study 27068695 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin (300 mg oral doses)
Number of subjects: 268
Study 27068695 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 268
Study 22889073 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to failure information in individuals with obsessive passion
Number of subjects: 0
Study 22889073 — intervention group
Group type: COMPARATOR
Intervention: Exposure to success or failure information in individuals with harmonious passion
Number of subjects: 0
Study 22889073 — intervention group
Group type: EXPERIMENTAL
Intervention: Framing of performance task with important negative consequences for the self after failure information
Number of subjects: 0
Study 22889073 — intervention group
Group type: COMPARATOR
Intervention: Framing of performance task as inconsequential after failure information
Number of subjects: 0
Study 21069585 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-administered cognitive-behavioral therapy (T-CBT)
Number of subjects: 127
Study 21069585 — intervention group
Group type: COMPARATOR
Intervention: Telephone-administered supportive emotion-focused therapy (T-SEFT)
Number of subjects: 127
Study 19814748 — intervention group
Group type: EXPERIMENTAL
Intervention: Flexometallic tracheal tube
Number of subjects: 60
Study 19814748 — intervention group
Group type: COMPARATOR
Intervention: ILMA tube
Number of subjects: 60
Study 16622262 — intervention group
Group type: EXPERIMENTAL
Intervention: Dermoscopy evaluation arm
Number of subjects: 73
Study 16622262 — intervention group
Group type: COMPARATOR
Intervention: Naked-eye evaluation arm
Number of subjects: 73
Study 15596679 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone propionate (250 microg bid)
Number of subjects: 49
Study 15596679 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 11269767 — intervention group
Group type: EXPERIMENTAL
Intervention: Topical allergen challenge
Number of subjects: 0
Study 11269767 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with nasal allergy
Number of subjects: 0
Study 11269767 — intervention group
Group type: COMPARATOR
Intervention: Controls (not specified)
Number of subjects: 0
Study 9821833 — intervention group
Group type: EXPERIMENTAL
Intervention: Nicotine patch
Number of subjects: 802
Study 9821833 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 802
Study 8310985 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil
Number of subjects: 0
Study 8310985 — intervention group
Group type: EXPERIMENTAL
Intervention: Rapeseed oil with 1 g squalene for 9 weeks
Number of subjects: 0
Study 8310985 — intervention group
Group type: COMPARATOR
Intervention: Control (rapeseed oil without squalene)
Number of subjects: 0
Study 8310985 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 g squalene/d for 6 weeks
Number of subjects: 0
Study 3396238 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous magnesium (Mg) therapy for 48 hours
Number of subjects: 270
Study 3396238 — intervention group
Group type: COMPARATOR
Intervention: Placebo therapy
Number of subjects: 270
Study 27297443 — intervention group
Group type: EXPERIMENTAL
Intervention: Small-sided ball game group (SSG)
Number of subjects: 295
Study 27297443 — intervention group
Group type: EXPERIMENTAL
Intervention: Circuit strength training group (CST)
Number of subjects: 295
Study 27297443 — intervention group
Group type: COMPARATOR
Intervention: Control group (CON)
Number of subjects: 295
Study 26095455 — intervention group
Group type: EXPERIMENTAL
Intervention: Tapentadol PR 50 mg (titrated to maximum 250 mg)
Number of subjects: 0
Study 26095455 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone/naloxone PR 10 mg/5 mg (titrated to maximum 40 mg/20 mg plus oxycodone PR 10 mg)
Number of subjects: 0
Study 25808944 — intervention group
Group type: EXPERIMENTAL
Intervention: Capecitabine (Cape)
Number of subjects: 0
Study 25808944 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐deoxy‐5‐fluorocytidine (DFCR)
Number of subjects: 0
Study 25808944 — intervention group
Group type: EXPERIMENTAL
Intervention: 5'‐deoxy‐5‐fluorouridine (DFUR)
Number of subjects: 0
Study 25808944 — intervention group
Group type: EXPERIMENTAL
Intervention: 5‐fluorouracil (5‐FU)
Number of subjects: 0
Study 23707930 — intervention group
Group type: EXPERIMENTAL
Intervention: Eplerenone
Number of subjects: 23
Study 23707930 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21940331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of metoclopramide (15 minutes before swallowing CE)
Number of subjects: 177
Study 21940331 — intervention group
Group type: COMPARATOR
Intervention: Control group (no metoclopramide)
Number of subjects: 177
Study 21940331 — intervention group
Group type: EXPERIMENTAL
Intervention: Intramuscular injection of metoclopramide
Number of subjects: 177
Study 18332401 — intervention group
Group type: EXPERIMENTAL
Intervention: Psyllium supplementation at 7 or 14 g/d for 3 months
Number of subjects: 158
Study 18332401 — intervention group
Group type: COMPARATOR
Intervention: Control group (no supplements)
Number of subjects: 158
Study 16520350 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (50 mg i.v. once weekly)
Number of subjects: 34
Study 16520350 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid (500 microg/min intra-arterially)
Number of subjects: 34
Study 16520350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 16520350 — intervention group
Group type: EXPERIMENTAL
Intervention: Folinic acid
Number of subjects: 34
Study 14605047 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled fluticasone propionate (FP) 800 microg/d for 2 weeks
Number of subjects: 10
Study 14605047 — intervention group
Group type: COMPARATOR
Intervention: High-dose ICS (group B)
Number of subjects: 10
Study 14605047 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose FP (group A)
Number of subjects: 10
Study 10883990 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mL of 0.25 % bupivacaine instilled into the gallbladder bed and Calot's triangle area
Number of subjects: 75
Study 10883990 — intervention group
Group type: COMPARATOR
Intervention: No bupivacaine instillation
Number of subjects: 75
Study 8883017 — intervention group
Group type: EXPERIMENTAL
Intervention: A1(OH)3 1 tablet 3 times per day (about 302 mg/day of elemental A1) for 3 months
Number of subjects: 55
Study 8883017 — intervention group
Group type: COMPARATOR
Intervention: Control group (no A1 exposure)
Number of subjects: 55
Study 8883017 — intervention group
Group type: EXPERIMENTAL
Intervention: A1(OH)3
Number of subjects: 55
Study 8140182 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluvoxamine and exposure therapy (group Fe)
Number of subjects: 60
Study 8140182 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure therapy with placebo (group Pe)
Number of subjects: 60
Study 8140182 — intervention group
Group type: COMPARATOR
Intervention: Antiexposure therapy with fluvoxamine (group F)
Number of subjects: 60
Study 3524320 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 26
Study 3524320 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study 29680962 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive Cognitive Bias Modification training for Interpretation (CBM-I)
Number of subjects: 69
Study 29680962 — intervention group
Group type: COMPARATOR
Intervention: Neutral control-CMB-I-training
Number of subjects: 69
Study 26485620 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose CT screening (5 annual scans)
Number of subjects: 4104
Study 23249766 — intervention group
Group type: EXPERIMENTAL
Intervention: Enriched milk group (EMG)
Number of subjects: 101
Study 23249766 — intervention group
Group type: COMPARATOR
Intervention: Placebo milk group (PMG)
Number of subjects: 101
Study 23249766 — intervention group
Group type: COMPARATOR
Intervention: Control group (CG)
Number of subjects: 101
Study 23106107 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 3 × 150 mg
Number of subjects: 125
Study 23106107 — intervention group
Group type: EXPERIMENTAL
Intervention: Secukinumab 3 × 75 mg
Number of subjects: 125
Study 23106107 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 125
Study 21967800 — intervention group
Group type: EXPERIMENTAL
Intervention: SMATH® system (automatic thermomechanic massage)
Number of subjects: 72
Study 21967800 — intervention group
Group type: COMPARATOR
Intervention: Sham therapy (medical device without active principles)
Number of subjects: 72
Study 21967800 — intervention group
Group type: EXPERIMENTAL
Intervention: SMATH® system
Number of subjects: 72
Study 18552606 — intervention group
Group type: EXPERIMENTAL
Intervention: Acupuncture (needle or electroacupuncture)
Number of subjects: 1456
Study 16371228 — intervention group
Group type: EXPERIMENTAL
Intervention: Active management of the third stage of labor with 600 mcg of oral misoprostol
Number of subjects: 1200
Study 16371228 — intervention group
Group type: COMPARATOR
Intervention: Current government guidelines for the prevention of PPH (control group)
Number of subjects: 1200
Study 14616378 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% alpha-lipoic acid cream
Number of subjects: 33
Study 14616378 — intervention group
Group type: COMPARATOR
Intervention: Placebo cream
Number of subjects: 33
Study 10781516 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin
Number of subjects: 160
Study 10781516 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 160
Study 9203484 — intervention group
Group type: EXPERIMENTAL
Intervention: Physiotherapy and biofeedback
Number of subjects: 40
Study 9203484 — intervention group
Group type: COMPARATOR
Intervention: Physiotherapy alone
Number of subjects: 40
Study 1557594 — intervention group
Group type: EXPERIMENTAL
Intervention: Training with sleep markers (A, B, C) and feedback
Number of subjects: 10
Study 1557594 — intervention group
Group type: COMPARATOR
Intervention: Control condition (no feedback, no markers)
Number of subjects: 10
Study 6372422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mexiletine
Number of subjects: 0
Study 6372422 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 6372422 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine
Number of subjects: 0
Study 31321071 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day fluoxetine for 60 days
Number of subjects: 20
Study 31321071 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for 60 days
Number of subjects: 20
Study 29604295 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9‐THC
Number of subjects: 21
Study 29604295 — intervention group
Group type: EXPERIMENTAL
Intervention: Δ9‐THC + CBD
Number of subjects: 21
Study 29604295 — intervention group
Group type: COMPARATOR
Intervention: CBD
Number of subjects: 21
Study 29604295 — intervention group
Group type: EXPERIMENTAL
Intervention: CP‐55940
Number of subjects: 21
Study 29604295 — intervention group
Group type: COMPARATOR
Intervention: CP‐55940 + AM‐251
Number of subjects: 21
Study 29604295 — intervention group
Group type: COMPARATOR
Intervention: Vehicle
Number of subjects: 21
Study 27368881 — intervention group
Group type: EXPERIMENTAL
Intervention: Palbociclib (125 mg daily; 3 weeks on/1 week off) with fulvestrant (500 mg intramuscular injection)
Number of subjects: 521
Study 27368881 — intervention group
Group type: COMPARATOR
Intervention: Placebo with fulvestrant (500 mg intramuscular injection)
Number of subjects: 521
Study 25191661 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5mg/kg oral midazolam premedication
Number of subjects: 62
Study 25191661 — intervention group
Group type: COMPARATOR
Intervention: No medication (control group)
Number of subjects: 62
Study 23456359 — intervention group
Group type: EXPERIMENTAL
Intervention: Everolimus-eluting stent (EES)
Number of subjects: 278
Study 23456359 — intervention group
Group type: COMPARATOR
Intervention: Sirolimus-eluting stent (SES)
Number of subjects: 278
Study 20082603 — intervention group
Group type: EXPERIMENTAL
Intervention: Veralipride (100 mg/day)
Number of subjects: 24
Study 20082603 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study 18786287 — intervention group
Group type: EXPERIMENTAL
Intervention: Amniocentesis-based management
Number of subjects: 40
Study 18786287 — intervention group
Group type: COMPARATOR
Intervention: Expectant management
Number of subjects: 40
Study 15960574 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.625 mg/day of conjugated estrogen
Number of subjects: 17
Study 15960574 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 17
Study 12024136 — intervention group
Group type: EXPERIMENTAL
Intervention: Magnetic endoscope imaging (imager view)
Number of subjects: 122
Study 12024136 — intervention group
Group type: COMPARATOR
Intervention: Standard colonoscopy (without imager view)
Number of subjects: 122
Study 12198787 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit test with weakly related word pairs
Number of subjects: 0
Study 12198787 — intervention group
Group type: EXPERIMENTAL
Intervention: Implicit test with strongly related word pairs
Number of subjects: 0
Study 12198787 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit test with weakly related word pairs
Number of subjects: 0
Study 12198787 — intervention group
Group type: EXPERIMENTAL
Intervention: Explicit test with strongly related word pairs
Number of subjects: 0
Study 7669311 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 1 mg
Number of subjects: 45
Study 7669311 — intervention group
Group type: EXPERIMENTAL
Intervention: Guanfacine 0.5 mg
Number of subjects: 45
Study 7669311 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 45
Study 2279253 — intervention group
Group type: EXPERIMENTAL
Intervention: Ibopamine 100 mg t.i.d.
Number of subjects: 12
Study 2279253 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 876918 — intervention group
Group type: EXPERIMENTAL
Intervention: Methyldopa
Number of subjects: 110
Study 876918 — intervention group
Group type: COMPARATOR
Intervention: Guanethidine
Number of subjects: 110
Study 876918 — intervention group
Group type: COMPARATOR
Intervention: Debrisoquine
Number of subjects: 110
Study 31174452 — intervention group
Group type: EXPERIMENTAL
Intervention: Neoadjuvant chemotherapy (NAC)
Number of subjects: 944
Study 31174452 — intervention group
Group type: COMPARATOR
Intervention: Radical cystectomy (RC) alone
Number of subjects: 944
Study 27552722 — intervention group
Group type: EXPERIMENTAL
Intervention: Canine-to-canine retainer bonded to the canines
Number of subjects: 64
Study 27552722 — intervention group
Group type: EXPERIMENTAL
Intervention: Bonded twistflex retainer 3-3, bonded to each tooth
Number of subjects: 64
Study 27552722 — intervention group
Group type: EXPERIMENTAL
Intervention: Both retainers
Number of subjects: 64
Study 25371450 — intervention group
Group type: EXPERIMENTAL
Intervention: Atomoxetine
Number of subjects: 925
Study 23836811 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment group (6 group treatment sessions)
Number of subjects: 221
Study 23836811 — intervention group
Group type: COMPARATOR
Intervention: Usual care (no psychological interventions)
Number of subjects: 221
Study 23836811 — intervention group
Group type: EXPERIMENTAL
Intervention: Adjustment group
Number of subjects: 221
Study 21269526 — intervention group
Group type: EXPERIMENTAL
Intervention: 6% HES 130/0.4 in Ringer's acetate
Number of subjects: 800
Study 21269526 — intervention group
Group type: COMPARATOR
Intervention: Ringer's acetate alone
Number of subjects: 800
Study 19638505 — intervention group
Group type: EXPERIMENTAL
Intervention: Genistein treatment
Number of subjects: 24
Study 19638505 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 24
Study 16360972 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN plus ribavirin (18 microg CIFN for 8 weeks, then 9 microg for 40 weeks)
Number of subjects: 77
Study 16360972 — intervention group
Group type: COMPARATOR
Intervention: CIFN plus ribavirin (9 microg CIFN for 48 weeks)
Number of subjects: 77
Study 16360972 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN plus ribavirin (both interventions)
Number of subjects: 77
Study 16360972 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN plus ribavirin (induction-dosing)
Number of subjects: 77
Study 16360972 — intervention group
Group type: EXPERIMENTAL
Intervention: CIFN plus ribavirin (sustained responders and relapse patients)
Number of subjects: 77
Study 15296484 — intervention group
Group type: EXPERIMENTAL
Intervention: Term pregnancy milk (Interval A)
Number of subjects: 33
Study 15296484 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm pregnancy milk (Interval A)
Number of subjects: 33
Study 15296484 — intervention group
Group type: EXPERIMENTAL
Intervention: Term pregnancy serum (Interval A)
Number of subjects: 33
Study 15296484 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm pregnancy serum (Interval A)
Number of subjects: 33
Study 15296484 — intervention group
Group type: EXPERIMENTAL
Intervention: Term pregnancy milk (Interval B)
Number of subjects: 33
Study 15296484 — intervention group
Group type: EXPERIMENTAL
Intervention: Preterm pregnancy milk (Interval B)
Number of subjects: 33
Study 11095445 — intervention group
Group type: EXPERIMENTAL
Intervention: Yohimbine (0.4 microg/kg)
Number of subjects: 12
Study 11095445 — intervention group
Group type: EXPERIMENTAL
Intervention: Naloxone (125 microg/kg)
Number of subjects: 12
Study 11095445 — intervention group
Group type: COMPARATOR
Intervention: Placebo (0.9% saline)
Number of subjects: 12
Study 9494772 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg norethisterone
Number of subjects: 24
Study 9494772 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg norethisterone acetate
Number of subjects: 24
Study 9494772 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg norethisterone acetate
Number of subjects: 24
Study 7692687 — intervention group
Group type: EXPERIMENTAL
Intervention: 3-week therapy series of ultrasound (6 times a week)
Number of subjects: 150
Study 7692687 — intervention group
Group type: EXPERIMENTAL
Intervention: 6-week therapy series of ultrasound (3 times a week)
Number of subjects: 150
Study 7692687 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-week therapy series of ultrasound (2 times a week)
Number of subjects: 150